We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer.
- Authors
Kim, Hyeong; Ryu, Min-Hee; Zang, Dae; Ryoo, Baek-Yeol; Yang, Dae; Cho, Ji; Lim, Man; Kim, Min-Jeong; Han, Boram; Choi, Dae; Kim, Jung; Jung, Joo; Song, Hunho; Park, Choong; Kang, Yoon-Koo
- Abstract
Background: Although the docetaxel, 5-fluorouracil, and cisplatin triplet has yielded significant improvements in time to progression, overall survival, and overall response rate, the high incidence of severe adverse events limits the use of the docetaxel, 5-fluorouracil, and cisplatin triplet. To overcome this limitation, we evaluated the efficacy and safety of the combination of docetaxel, oxaliplatin, and S-1 for the treatment of metastatic gastric cancer. Methods: Chemotherapy-naive patients with pathologically proven unresectable recurrent or metastatic gastric adenocarcinoma were assessed for eligibility. Docetaxel at 52.5 mg/m and oxaliplatin at 105 mg/m were administered intravenously on day 1, and S-1 was administered orally at 80 mg/m on days 1-14 of every 21-day cycle. Results: Forty-four patients (median age 54.5 years) were enrolled. All patients had metastatic disease. A total of 340 cycles of chemotherapy were administered (median of eight cycles per patient; range 1-36 cycles). Toxicities were evaluated in 43 patients, and the responses were evaluated in 40 patients. Major toxicities included grade 3/4 neutropenia (37.2 %) and leukopenia (27.9 %). The overall response rate was 54.5 % [95 % confidence interval (CI) 40.1-68.3 %] in the intention-to-treat population. The median progression-free survival and overall survival were 7.6 months (95 % CI 6.2-9.0 months) and 12.0 months (95 % CI 6.9-17.2 months), respectively. Conclusion: These data suggest that the docetaxel, oxaliplatin, and S-1 combination regimen is effective and relatively well tolerable, and it seems to have potential to be a reasonable therapeutic strategy in patients with metastatic or recurrent gastric cancer.
- Subjects
STOMACH cancer treatment; DOCETAXEL; OXALIPLATIN; FLUOROURACIL; COMBINATION drug therapy; PROGRESSION-free survival; CANCER chemotherapy; CLINICAL drug trials; THERAPEUTICS
- Publication
Gastric Cancer, 2016, Vol 19, Issue 2, p579
- ISSN
1436-3291
- Publication type
Article
- DOI
10.1007/s10120-015-0503-2